BioSpace News Archive

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered non-small cell lung cancer and thyroid cancer patients who may be suitable for LOXO-292, Lilly’s RET inhibitor

One in four Canadian men (28 per cent) fear their job could be at risk if they discussed their mental health at work, according to new research by Movember.

Aptorum Group Limited announces that it has initiated investigational new drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or “S. aureus”) including methicillin-resistant Staphylococcus aureus (MRSA, i.e., one of the commonly known “super-bugs”) based on a novel anti-virulence approach.

Aptorum Group Limited provided a business update and announced financial results for the six months ended June 30, 2019.

The advanced compounding bases cover a broad range of therapeutic categories.

Includes $3.5M from group of U.S. accredited investors with deep expertise in 3D printing

Theravance Biopharma, Inc. announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose and multiple-ascending dose clinical trial of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase inhibitor for inflammatory lung diseases.

STAAR Surgical Company is announcing the EVO ICL Clinical Program which will be presented by Ophthalmic Surgeons to Ophthalmic Surgeons at its invitation only Surgical Experts Summit.

Detailed Imeglimin Phase 3 TIMES 1 results to be presented at EASD; session chaired by Ralph DeFronzo, M.D., leading academic diabetes expert

SpePharm AG, a subsidiary of Norgine B.V., announced that the United States District Court for the District of Delaware ruled on 4th September 2019 in favour of SpePharm in its proceeding against Eisai Inc., upholding SpePharm’s licensed rights for SALAGEN® through April 2026.